Fisher-Wallace

A Pioneer of Prescription Wearables

By Kelly Roman, CEO & Co-Founder

Fisher Wallace Laboratories, the market leader in prescription wearable technology for the treatment of neuropsychiatric disorders, recently announced the closing of a funding round that will provide the company with $2.5M of capital to pursue its growth strategy. The round was led by SHUFL Capital, a leading early-stage investor in the Sleep, Health, Fitness and Leisure sectors founded by British businessman and growth investor Simon Webster. The financing closed simultaneously as Fisher Wallace announced the launch of an equity crowdfunding campaign through StartEngine aimed to raise $1.9M. This latest round of financing follows the recent (October 2021) close of Fisher Wallace’s first equity crowdfunding campaign that raised $4.7M. The company has since launched a new equity crowdfunding campaign: www.startengine.com/fisherwallace

With historic spikes in depression, anxiety, and…

Medical device startup Fisher Wallace Laboratories has been named one of “5 Health-Tech Startups to Watch in 2021” by Entrepreneur magazine and has raised nearly $3 million on StartEngine, a leading equity crowdfunding platform. The majority of the company’s investors are its own customers – people who have used Fisher Wallace’s prescription wearable to treat anxiety, depression and insomnia.

The company’s Version 1 device has sold over 70,000 units via 14,000 prescribers. Version 2 is currently being designed by Eric Fields, the award-winning designer of Beats and Nest products, and will feature a mobile app that tracks symptoms and cognitive performance. Version 1 looks like a hospital device – true to its origins – but Version 2 will have the look and feel of a modern consumer wearable while still requiring a prescription and delivering the same FDA-Cleared brain stimulation as its predecessor.

The dev…

Fisher Wallace has raised millions via equity crowdfunding to redefine mental health treatment.

The CEO of Fisher Wallace Laboratories, a medical device startup that is disrupting the mental health industry with its FDA-Cleared wearable brain stimulation technology, envisions a near-future when drug therapy is the last resort for treating depression, anxiety, and insomnia. The company has raised millions on the equity crowdfunding platform StartEngine to compete with Big Pharma by selling an FDA-Cleared device that’s affordable out-of-pocket, causes almost no side effects, and has been shown to be effective in recent clinical trials.

“The most commonly prescribed antidepressants were developed in the 1980s, cause side effects more often than they produce symptom remission, cost a fortune when you include doctor visits, and need to pass through the digestive system before reaching the brain,” explains Kelly Roman, CEO of Fisher Wallace.

Fisher Wal…